Newsroom

Sorted by: Latest

-

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in reducing moderate and severe exacerbations in a broad population of patients with chronic obstructive pulmonary disease (COPD) still experiencing exacerbations while on inhaled standard of care.1,2 The trials included former and current smokers, and patients across...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 07.09.2026 UIGB IE00079WNSI6    5,866.00 GBP    168,651.76   28.751  ...
-

UK Debt Management Office UK Regulatory Announcement: Issue of Debt

LONDON--(BUSINESS WIRE)--  RE-OPENING AND PRICING OF 5 3/8% TREASURY GILT 2056 BY SYNDICATION The UK Debt Management Office, jointly with the five lead managers, announces the fixed re-offer price for the syndicated issue. Gilt Issued 5 3/8% Treasury Gilt 2056 ISIN GB00BT7J0241 Issuance Size GBP 4.25 billion (nominal) Re-offer Price 93.806 Re-offer Yield 5.8168% Reference Bond 4 1/4% Treasury Gilt 2055 Reference Bond ISIN GB00B06YGN05 Spread to Reference Bond +0.75 bps Settlement Date 09 Septem...
-

IonQ Publishes World’s First Fully Compiled, End-to-End Blueprint for Breaking 256-Bit Elliptic-Curve Signatures

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading full-stack quantum platform and foundry, today published the first complete, end-to-end fault-tolerant resource estimate for running Shor’s algorithm. The historic paper by IonQ’s research team uses the recently published Walking Cat architecture to demonstrate how a specific application can be optimized for a trapped-ion quantum computer. This work concludes that a 20,000-physical-qubit IonQ quantum computer is expected...
-

Marcus Theatres Sets More Records with Highest Summer Revenue of All Time

MILWAUKEE--(BUSINESS WIRE)--Marcus Theatres®, the nation’s fourth largest theatre circuit and a division of Marcus Corporation (NYSE: MCS), announced today that it recorded its highest total revenue for the summer moviegoing season in company history, defined as the first Friday in May through Labor Day. Fueled by blockbuster hits and a diverse slate of summer releases that appealed to a wide range of audiences, summer records set at Marcus Theatres include: Highest total summer revenue in comp...
-

GAMCO Investors UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: GAMCO Investors, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  ...
-

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human can...
-

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical upd...
-

Best’s Special Report: U.S. Property/Casualty Industry Nearly Tripled Net Underwriting Income in First-Half 2026

OLDWICK, N.J.--(BUSINESS WIRE)--The U.S. property/casualty (P/C) industry recorded $31.2 billion in net underwriting income in the first half of 2026, nearly three times the $10.9 billion posted in the same prior-year period, according to a new AM Best report. These preliminary results are detailed in a new Best’s Special Report, titled, “First Look: Six-Month 2026 US Property/Casualty Financial Results,” and the data is derived from companies’ six-month 2026 interim period statutory statements...
-

Soluna Finishes Kati 1 and Secures Conditional Base Load Position for All 166 MW in ERCOT

ALBANY, N.Y.--(BUSINESS WIRE)--Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ: SLNH), a developer of green data centers for intensive computing applications, including AI and Bitcoin mining, today announced two milestones at its Project Kati campus in Willacy County, Texas. The Company has energized the final 14 MW at Project Kati 1, completing the 83 MW site, and has been notified that ERCOT has conditionally classified the full 166 MW Kati campus, including the planned Kati 2 AI ex...